Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425568 · ClinicalTrials.gov registry record
Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR
A clinical trial of Hypogonadism, sponsored by Lamm, Steven, M.D..
- Completed
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT00425568 is a study of Hypogonadism that has completed, run by Lamm, Steven, M.D.. The registered enrollment target is 30 participants, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00425568, a study of Hypogonadism, has completed, sponsored by Lamm, Steven, M.D..
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Low testosterone may be responsible for "soft" erections in men. The purpose of our study is to see whether the daily application of a testosterone gel to raise testosterone levels will also increase the "hardness" of a man's erection.
Conditions Studied
Interventions
- DRUG AndroGel (Transdermal Testosterone Gel)
Study Locations (1)
New York
- Steven Lamm, M.D. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425568
The ClinicalTrials.gov registry entry for NCT00425568 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (75% lower). The listed sponsor is Lamm, Steven, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which AndroGel (Transdermal Testosterone Gel) is the first listed.
NCT00425568 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00425568 about?
NCT00425568 is a clinical study titled "Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR". Low testosterone may be responsible for "soft" erections in men. The purpose of our study is to see whether the daily application of a testosterone gel to raise testosterone levels will also increase the "hardness" of a man's erection.
What is the current status of trial NCT00425568?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2005-12.
What conditions does trial NCT00425568 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT00425568?
The interventions under investigation include: AndroGel (Transdermal Testosterone Gel) (DRUG).
Who is sponsoring clinical trial NCT00425568?
This trial is sponsored by Lamm, Steven, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425568 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
-
Adaptions and Resiliency to Multi-Stressor OpeRations
RECRUITING · Phase 4
-
Inherited Reproductive Disorders
RECRUITING
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
RECRUITING
-
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.